$1.16
-0.04 (-3.33%)
Open$1.21
Previous Close$1.20
Day High$1.21
Day Low$1.13
52W High$3.60
52W Low$0.84
Volume—
Avg Volume116.2K
Market Cap4.57M
P/E Ratio—
EPS$-3.76
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,255.2% upside
Current
$1.16
$1.16
Target
$38.92
$38.92
$24.59
$38.92 avg
$51.00
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 555.8K | 518.1K | 501.1K |
| Net Income | 113.5K | 116.0K | 100.3K |
| Profit Margin | 20.4% | 22.4% | 20.0% |
| EBITDA | 245.4K | 221.0K | 210.9K |
| Free Cash Flow | 70.8K | 77.8K | 93.1K |
| Rev Growth | -5.3% | +6.0% | -5.8% |
| Debt/Equity | 0.43 | 0.40 | 0.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.53 | -1.09% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $361.16 | +0.17% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.13 | -0.16% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $494.74 | -0.98% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $628.06 | -0.59% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $297.43 | +1.33% | 69.3 | 39.97B |